The safety and efficacy of anti-PD-1/anti-PD-L1 antibody therapy in the treatment of previously treated, advanced gastric or gastro-oesophageal junction cancer: A meta-analysis of prospective clinical trials - 20/03/20
, Yanpeng Xing , Xuan Sun , Jian Suo ⁎ Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 12 |
| Iconographies | 6 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Nine prospective clinical trials were identified in our meta-analysis and all studies were published in recent three years. |
• | The safety and efficacy outcomes were calculated and evaluated in our study. The results indicated that anti-PD-1/anti-PD-L1 antibody therapy has an effectual antitumor activity and controllable adverse effects in advanced gastric or gastro-oesophageal junction cancer patients. |
• | The results also showed that patients with positive PD-L1 expression had better objective response rate from anti-PD-1/anti-PD-L1 antibody therapy. |
Summary |
Introduction |
So far, anti-PD-1/anti-PD-L1 antibody therapy is reportedly in treating gastric cancer or gastro-oesophageal junction cancer (GC/GEJC) in a number of clinical trials. Based on this, we conducted current meta-analysis to assess the safety and efficacy of anti-PD-1/anti-PD-L1 antibody for previously treated advanced GC/GEJC patients.
Methods |
We searched five electronic databases for eligible records. Outcomes were presented and analyzed by objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and adverse effects (AEs).
Results |
Nine records involving 1388 participants were selected in our study. The pooled ORR, DCR, OS rate (6 month), PFS rate (6 month), OS rate (12 month) and PFS rate (12 month) were 10% (95% confidence interval [CI]: 6%–14%), 32% (95%CI: 25%–38%), 52% (95%CI: 44%–61%), 18% (95%CI: 13%–24%), 40% (95%CI: 31%–48%) and 8% (95%CI: 5%–10%), respectively. Meanwhile, grade≥3 AEs rate was 12% (95% CI: 10%-15%). Programmed death ligand 1 (PD-L1) positive cases had higher rate of ORR (odds ratio [OR]: 3.75, 95%CI: 2.09–6.74, P=0.58) compared with negative cases.
Conclusion |
The results indicated that anti-PD-1/anti-PD-L1 antibody therapy has an effectual anti-tumor activity and controllable AEs in advanced GC/GEJC patients. Furthermore, overexpression of PD-L1 in advanced GC/GEJC patients had better ORR from anti-PD-1/anti-PD-L1 antibody therapy (PROSPERO registration number: CRD42018116480).
Le texte complet de cet article est disponible en PDF.Keywords : Anti-PD-1/anti-PD-L1 antibody, Gastric cancer, Gastro-oesophageal junction cancer, Meta-analysis
Abbreviations : AE, CI, DCR, GC, GEJC, OR, ORR, PFS, OS
Plan
Vol 44 - N° 2
P. 211-222 - avril 2020 Retour au numéro
Article précédent
- Temporal trends of pancreatic ductal adenocarcinoma in young adults in the United States: A Population-Based Study
- Mohamed M. Gad, Anas M. Saad, Muneer J. Al-Husseini, Youssef M. Abdel-Gawad, Obai M. Alsalhani, Razan Alhaddad, Bashar Mohamad, Mohannad Abou Saleh, Carlos Roberto Simons-Linares
- Effectiveness and safety of biologics in pediatric inflammatory bowel disease: Real-life data from the Sicilian Network
- Anna Claudia Romeo, Marco Ventimiglia, Valeria Dipasquale, Ambrogio Orlando, Michele Citrano, Salvatore Pellegrino, Salvatore Accomando, Mario Cottone, Claudio Romano
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?